Trial Profile
A Pilot Study of Neo-adjuvant Temsirolimus in Patients With Advanced Renal Cell Carcinoma Undergoing Definitive Therapy With Radical Nephrectomy, or Cytoreductive Nephrectomy: Analysis if Serum and Tissue Biomarkers
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 18 Dec 2015
Price :
$35
*
At a glance
- Drugs Temsirolimus (Primary)
- Indications Renal cell carcinoma
- Focus Biomarker; Therapeutic Use
- 15 Dec 2015 Status changed from active, no longer recruiting to completed as per ClinicalTrials.gov record.
- 14 Jul 2014 Planned End Date changed from 1 Dec 2014 to 1 Sep 2014, according to ClinicalTrials.gov record.
- 14 Jul 2014 Planned primary completion date changed from 1 Apr 2014 to 1 Aug 2014, according to ClinicalTrials.gov record.